The Business Case for Medication Therapy Management in Australia

Medication therapy management (MTM) is often described as a clinical service, yet it also has a clear commercial role in community pharmacy. A structured review can identify medicine-related problems, improve adherence and give patients a stronger reason to return to the pharmacy for professional care.

The opportunity is especially relevant in Australia, where pharmacists work within a complex system shaped by the Pharmaceutical Benefits Scheme (PBS), Medicare-funded services, private consultations and growing demand for support with chronic disease. Customers are also becoming more comfortable seeking advice from a pharmacist before booking a GP appointment or attending hospital.

A viable MTM service does not mean adding an unplanned conversation to an already busy dispensary. It means creating a repeatable consultation pathway, defining its value, training the team and tracking results. When managed carefully, the service can strengthen patient outcomes while supporting a more resilient pharmacy business.

What medication therapy management includes

MTM is a comprehensive approach to reviewing a patient’s medicines and helping them use those medicines safely and effectively. It may cover prescription medicines, over-the-counter products, complementary therapies, adherence barriers, adverse effects, monitoring requirements and practical questions about daily routines.

A consultation can reveal duplication, unsuitable dosing times, untreated symptoms, medicine interactions or confusion caused by changes in therapy. It can also uncover problems that patients may not mention during dispensing, such as avoiding a medicine because of cost, difficulty opening packaging or concern about dependence.

In Australia, MTM can sit alongside established services such as Home Medicines Reviews, Residential Medication Management Reviews and medication reviews delivered through community pharmacy programs. The exact eligibility, funding and documentation requirements differ between services, so a pharmacy should distinguish between a funded program and a privately offered clinical consultation.

That distinction protects both the patient and the business. A pharmacist can explain what the service includes, what it costs, whether a referral is needed and what follow-up will occur. Clear boundaries make the service easier to market and reduce the risk of promising outcomes that depend on another health professional.

Why patients and referrers value the service

Many patients experience their medication list as a collection of separate instructions rather than a coordinated treatment plan. An MTM consultation gives them time to connect the pieces. The pharmacist can explain the purpose of each medicine, identify practical obstacles and help the patient prepare for a GP appointment when a treatment issue requires medical review.

This is valuable for people taking multiple medicines, older adults, patients recently discharged from hospital and those managing conditions such as diabetes, cardiovascular disease, asthma or depression. It can also help people who move between specialists and struggle to keep an accurate list of current medicines.

The service creates a stronger professional relationship with local prescribers. A concise, clinically relevant report that identifies a problem and proposes a reasonable action is more useful than a generic note. With patient consent, the pharmacist can communicate concerns to the GP, nurse practitioner or specialist and record the agreed follow-up.

Local access matters. A patient in suburban Melbourne may have several healthcare options nearby, while someone in regional New South Wales or Far North Queensland may face long travel times and limited appointment availability. A well-run pharmacy service can provide an accessible first point of support and direct patients to the right clinician when the issue exceeds the pharmacist’s scope.

How the service can generate commercial value

The most direct return comes from consultation income. A pharmacy may charge privately for a detailed medicine review, bundle a review with an existing care service or participate in a funded program where eligible. The financial model should account for pharmacist time, administration, private consultation-room use, follow-up calls and any reporting obligations.

The wider value is often just as important. Patients who receive thoughtful clinical support are more likely to regard the pharmacy as a healthcare destination rather than simply a place to collect prescriptions. That can improve retention, increase appropriate use of pharmacy services and support demand for vaccinations, dose administration aids, staged supply and health monitoring.

MTM can also improve the quality of business decisions. When a pharmacy tracks common problems, it may identify demand for adherence packaging, post-discharge support, chronic disease education or medicine synchronisation. The service therefore becomes a source of local insight rather than an isolated consultation product.

Owners should avoid judging the program only by the number of paid reviews. A patient who receives a review may prevent a future medicine-related problem, remain loyal to the pharmacy and refer a family member. These benefits are difficult to attribute perfectly, but they can be monitored through repeat visits, service uptake, referral sources and patient feedback.

Designing a financially sound workflow

A practical MTM workflow begins with patient identification. Pharmacy staff can look for high medicine counts, frequent early or late repeats, recent hospital discharge, confusion about directions, repeated questions or signs that a patient is not achieving the expected benefit. The pharmacist then confirms suitability and obtains consent before booking a protected consultation.

The consultation should use a standard template without becoming a rigid script. Core fields may include the complete medicine list, the patient’s treatment goals, adherence, allergies, adverse effects, monitoring, lifestyle factors and actions agreed with the patient. Standardisation reduces omissions and helps another pharmacist continue the care plan.

Time must be protected. If consultations are repeatedly interrupted by dispensing demands, the service will feel disorganised and margins will disappear. Appointment blocks, a private space and a clear handover process make the service more predictable. In a busy pharmacy in Parramatta or Adelaide, even two scheduled consultations per day may be more sustainable than accepting unlimited walk-ins.

The pharmacy should calculate its break-even point before launch. Include the pharmacist’s loaded hourly cost, software, training, administration and follow-up time. A price that looks attractive to patients can still be unprofitable if a 30-minute consultation routinely requires another 20 minutes of unpaid work.

Building referrals and community visibility

Patients need to understand the service in plain language. “A medicine check to help you get the best from your treatment” may be more approachable than a technical description of pharmacotherapy optimisation. Signage, the pharmacy website, prescription collection conversations and staff recommendations can all explain who may benefit.

Referral relationships should be developed ethically and patiently. Local GPs, practice nurses, aged-care teams, physiotherapists and hospital discharge coordinators may refer patients when they understand the pharmacist’s role. A short information sheet can outline eligibility, consultation length, reporting arrangements and the types of medicine-related problems the pharmacy can address.

Pain management is a useful area for professional collaboration. Pharmacists can help patients understand when a prescription analgesic may be appropriate, when an over-the-counter option may be sufficient and when urgent review is needed. A practical discussion of prescription and OTC pain relief can support consistent counselling within the team.

Opioid stewardship also provides a clear reason for a structured review. Patients receiving repeated opioid prescriptions may need assessment of benefit, risk, duration, sedation, constipation, dependence and safer alternatives. A pharmacy checklist can support consistent practice; the opioid stewardship checklist offers a useful model for thinking about governance and documentation.

Making clinical quality part of the business model

A profitable service still needs strong clinical governance. The pharmacist should work within professional standards, state and territory requirements, privacy obligations and the boundaries of the relevant funding arrangement. Patient consent, secure records and careful communication are essential when information is shared with another provider.

The service should also have an escalation policy. Red flags may include suspected overdose, severe adverse reactions, suicidal thoughts, uncontrolled symptoms, signs of medicine dependence or a patient who cannot safely manage medicines at home. The pharmacist needs to know when to contact the prescriber, refer to urgent care or call emergency services.

Training can make the service more consistent across the team. Staff should know how to identify suitable patients, introduce the service without pressure and book appointments accurately. Pharmacists may need additional development in motivational interviewing, deprescribing, health literacy, culturally safe care and communication with people experiencing cognitive impairment.

Resources from reputable organisations can support ongoing education, particularly when a service includes complex medicine information or patient-facing materials. A curated medication support resource may assist with broader education, provided the pharmacist evaluates its relevance, evidence base and commercial context before using it in practice.

Measuring outcomes and improving the offer

A small set of measures can demonstrate whether the service is delivering value. Useful indicators include completed consultations, no-show rates, referral sources, identified medicine-related problems, recommendations accepted by prescribers, follow-up completion and patient-reported confidence with medicines.

Financial measures should be reviewed alongside clinical outcomes. Track revenue per consultation, total pharmacist time, administration time, repeat bookings and changes in related service use. If the service attracts patients but consumes excessive unpaid labour, the workflow or pricing needs adjustment.

Patient feedback should be specific. Ask whether the pharmacist explained the medicines clearly, whether the consultation addressed the patient’s concerns and whether the agreed actions were easy to follow. A short survey or follow-up call can reveal barriers that a clinical template misses.

The review process should lead to practical changes. A pharmacy might shorten an intake form, create a referral template, add a follow-up appointment at seven days or reserve certain sessions for recently discharged patients. In smaller towns, outreach days may work better than daily appointments; in a large Sydney pharmacy, online bookings and structured recall may be more effective.

Growing the service without losing trust

Expansion should follow evidence of demand and operational control. Once the basic service works, the pharmacy may develop focused pathways for polypharmacy, respiratory medicines, diabetes, cardiovascular risk, mental health or transitions of care. Each pathway should have a defined patient group, consultation goal and escalation process.

The service should never become a sales conversation disguised as clinical care. Recommending a product is appropriate only when it meets a genuine patient need and is supported by sound professional reasoning. Trust is a commercial asset, but it is earned through transparent advice rather than aggressive promotion.

Pricing should also be transparent. Patients should know whether follow-up is included, what happens if a prescriber needs to be contacted and whether the consultation replaces or complements a funded review. For concession card holders and people facing financial hardship, the pharmacy may consider limited subsidies or prioritise funded pathways where available.

The strongest model is one that patients can understand, pharmacists can deliver consistently and the business can afford to maintain. Medication therapy management services become commercially meaningful when they solve real problems, create reliable professional relationships and produce measurable benefits for the people who use them.

Pharmacy owners and managers can begin with a small pilot: define the patient group, set a consultation price, train the team, schedule protected appointments and review the results after several weeks. Build the service around clinical integrity and local demand, then expand the parts that improve patient care and strengthen the pharmacy’s long-term role in the community.